On December 7, 2020, Ever Supreme applied for the addition of the cell therapy technology of "Allogenic immune cells (CIK) treating hematological malignancies after ineffective conventional therapy", has been approved by the Taiwan FDA.

Ever Supreme Cell Preparation Plant applied for additional technology for therapy in accordance with the RGSCTT, which was approved by the Taiwan FDA.

Ever Supreme is the contracted cell preparation site of China Medical University Hospital under the RGSCTT, and the hospital applied to Taiwan FDA for “Allogenic immune cells (CIK) treating hematological malignancies after unsuccessful conventional therapy”, and received approval by Taiwan FDA on Dec 7 2020 as a qualified GTP cell preparation site.

Permitted items in China Medical University Hospital the development plan is as followed:

(1)Excution of item: autologous immune cell therapy (CIK).
(2)Indications: Hematological malignancies after ineffective conventional treatment; cancer types: Hodgkin’s lymphoma, B-cell non-Hodgkin’s lymphoma, acute myeloid leukemia, acute lymphoid leukemia, chronic myelogenous leukemia, chronic lymphoid leukemia, multiple myeloma.
(3)Cell preparation site: Cell Preparation Sites of Ever Supreme Bio Technology Co., LTD.
(4)Validity: Dec 7 2020 to May 14, 2022.
BACK